posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.
Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Sumber: NBCLA - 🏆 319. / 59 Baca lebih lajut »
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Sumber: NBCNewYork - 🏆 270. / 63 Baca lebih lajut »
Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
Sumber: MarketWatch - 🏆 3. / 97 Baca lebih lajut »